A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing ...

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional ...

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and ...

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials; pulmonary fibrosis is a very serious disease, with a life prognosis ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

The field of PPF is moving towards a personalized, data-driven approach, emphasizing biomarker integration and risk stratification for early diagnosis and treatment. Recent guidelines standardized PPF ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, ...

Pediatric lung transplant specialist Christian Benden, MD, described the future for children who need lung transplants: fewer ...